TRENDING: You Don't Have To Dig Far To Cash In On Rare Earths Novo Nordisk (NVO) kicked off a new battle with Pfizer (PFE) on Thursday by making an unsolicited $6.5 billion bid for obesity-focused takeover target, Metsera (MTSR). The bid sent shock waves through Wall Street. "You wouldn't have expected a GLP-1 incumbent to be bidding here," Evercore ISI analyst Umer Raffat said in a report to clients. "But you know what the bigger surprise is? That Novo is basically offering a 50% termination fee." Pfizer a ...

On Thursday, Metsera Inc. (NASDAQ:MTSR) received an unsolicited acquisition proposal from Novo Nordisk A/S (NYSE:NVO).Metsera said the proposal constitutes a “Superior Company Proposal” as defined in Metsera’s existing Merger Agreement with Pfizer Inc (NYSE:PFE).In September, Pfizer agreed to acquire Metsera for $47.50 per share in cash, representing an enterprise value of approximately $4.9 billion.The acquisition brings a portfolio of differentiated oral and injectable incretin, non-incretin, and combinat ...

Metsera此前在9月已同意接受辉瑞最高73亿美元的收购方案。该公司周四表示，在诺和诺德的未经邀请的新报价公开后，认为后者"更 具优势"。诺和诺德——司美格鲁肽（Ozempic）与Wegovy减重药物的制造商——提出以每股56.50美元收购Metsera，对应总股权价值 65亿美元。此外，该交易还包括每股21.25美元的里程碑付款，若公司达到特定临床与监管目标，将再支付25亿美元。 诺和诺德此举在生物科技领域属罕见的主动收购，可能引发竞价战。辉瑞目前有四个工作日可提出更高报价。Metsera表示，辉瑞已告 知公司其"不认为Metsera有权将诺和诺德的报价认定为更优方案"。 整理 | GLP1减重宝典内容团队 丹麦制药巨头诺和诺德（Novo Nordisk）突袭美国制药公司辉瑞（Pfizer）对减重生物科技公司Metsera的收购计划，开出高达90亿美 元的新报价，引发对其遏制竞争的指控。 诺和诺德的举动发生在Doustdar今年8月上任之后。此前，前任CEO Lars Fruergaard Jørgensen因公司股价一年内暴跌逾50%而被罢免。 新任CEO已承诺将重心放在诺和诺德的核心领域——代谢疾病与 ...

美国生物制药企业Metsera(MTSR.US)大涨超21.5%，报63.46美元。诺和诺德(NVO.US)跌近3%，报49.86 美元。 消息面上，诺和诺德对Metsera发起一项收购要约，提出每股56.5美元的全现金报价，对应企业价值约60 亿美元。辉瑞今年9月宣布，已同意以每股47.50美元现金收购Metsera，对应企业价值约49亿美元。若达 到特定研发目标，辉瑞还将额外支付每股22.50美元，使得交易总价值达到73亿美元。(格隆汇) ...

Novo Nordisk said on Thursday that it had adhered to all restrictions under the Pfizer merger agreement in its unsolicited offer for drugmaker Metsera , and that the value of its proposal far exceeded... ...

Meta公司表现 - 股价下跌10.4% [1] - 季度盈利因一次性税费而出现暴跌 [1] 微软公司表现 - 股价下跌2.3% [1] - 第一季度业绩超过市场预期 [1] Alphabet公司表现 - 股价上涨7.3% [1] - 第三季度营收超过市场预期 [1] - 第三季度利润超过市场预期 [1] - 全年资本开支指引超过市场预期 [1] Metsera公司表现 - 股价上涨20.2% [1] - 诺和诺德提出以每股56.50美元的价格收购该公司 [1]

Invesco is an independent investment management firm dedicated to delivering an investment experience that helps people get more out of life.Be the first to know! Sign up for Invesco US Blog and get expert investment views as they post.Disclosure for all Invesco US articles: Before investing, carefully read the prospectus and/or summary prospectus and carefully consider the investment objectives, risks, charges and expenses. The information provided is for educational purposes only and does not constitute a ...

Novo Nordisk A/S (NYSE:NVO) is one of the Best Bargain Stocks to Buy in November. On October 22, Reuters reported that Novo Nordisk A/S (NYSE:NVO)’s top investor, the non-profit Novo Nordisk Foundation, decided to take control of the company’s board. It vowed a strong emphasis on the critical US market to fuel sales growth for Wegovy, and highlighted the need to move faster on the mass-market channels, reported Reuters. Notably, Americans are now seeking weight-loss drugs, such as Wegovy, not from their do ...

1. 美国三大股指期货小幅下跌，纳指期货跌0.35%，标普500指数期货跌0.24%，道指期货跌0.33%。 2. 欧股主要指数集体下跌，德国DAX指数跌0.15%，英国富时100指数跌0.61%，法国CAC指数跌 0.91%，欧洲斯托克50指数跌0.52%。 3. 商务部：美方将取消针对中国商品加征的10%"芬太尼关税"，暂停实施其9月29日公布的出口管制 50%穿透性规则一年。 4. 美联储如期降息25个基点，鲍威尔强调12月降息"远非定局"。 5. 美国和韩国达成贸易协议，韩国同意投资3500亿美元以换取降低关税。 6. OpenAI据报最快2026年申请上市，估值可能高达1万亿美元。 11. 礼来Q3营收同比增长54%至176亿美元，调整后每股收益7.02美元；上调全年收入预期。 12. 默沙东Q3销售额172.8亿美元，调整后每股收益2.58美元，均超预期。 13. Stellantis Q3收入同比增长13%至372亿欧元，美国关税已对今年造成约10亿欧元损失。 14. 壳牌Q3调整后利润54.3亿美元，超预期；宣布一项35亿美元的股票回购计划。 15. 企业云计算解决方案提供商ServiceNo ...

Novo Nordisk A/S made an unsolicited bid for US biotech firm Metsera Inc., sparking a heated battle with Pfizer Inc. to get their hands on weight-loss treatments that both drugmakers want in order to regain lost ground in the booming market. Novo offered to buy Metsera Inc. for at least $6.5 billion, seeking to trump an earlier agreed deal with Pfizer. Metsera called the new offer, which Bloomberg News reported earlier on Thursday, superior to the previous one from Pfizer that it had accepted last month. ...